Dopaminergic dysfunction in schizophrenia: salience attribution revisited.
A dysregulation of the mesolimbic dopamine system in schizophrenia patients may lead to aberrant attribution of incentive salience and contribute to the emergence of psychopathological symptoms like delusions. The dopaminergic signal has been conceptualized to represent a prediction error that indicates the difference between received and predicted reward. The incentive salience hypothesis states that dopamine mediates the attribution of "incentive salience" to conditioned cues that predict reward. This hypothesis was initially applied in the context of drug addiction and then transferred to schizophrenic psychosis. It was hypothesized that increased firing (chaotic or stress associated) of dopaminergic neurons in the striatum of schizophrenia patients attributes incentive salience to otherwise irrelevant stimuli. Here, we review recent neuroimaging studies directly addressing this hypothesis. They suggest that neuronal functions associated with dopaminergic signaling, such as the attribution of salience to reward-predicting stimuli and the computation of prediction errors, are indeed altered in schizophrenia patients and that this impairment appears to contribute to delusion formation.
Heinz
Andreas
A
Department of Psychiatry, Charité-Universitätsmedizin Berlin, Charité Campus Mitte, 10117 Berlin, Germany. andreas.heinz@charite.de
Schlagenhauf
Florian
F
D000818:Animals; D003213:Conditioning, Psychological / Q000502:physiology; D003702:Delusions / Q000175:diagnosis / Q000503:physiopathology / Q000523:psychology; D004298:Dopamine / Q000378:metabolism*; D006801:Humans; D008279:Magnetic Resonance Imaging; D009042:Motivation / Q000502:physiology*; D009415:Nerve Net / Q000503:physiopathology; D009474:Neurons / Q000502:physiology; D010101:Oxygen Consumption / Q000502:physiology; D018187:Personal Construct Theory; D049268:Positron-Emission Tomography; D017397:Prefrontal Cortex / Q000503:physiopathology; D017447:Receptors, Dopamine D1 / Q000502:physiology*; D017448:Receptors, Dopamine D2 / Q000502:physiology*; D012016:Reference Values; D012201:Reward; D012559:Schizophrenia / Q000175:diagnosis / Q000503:physiopathology*; D012565:Schizophrenic Psychology; D015398:Signal Transduction; D019966:Substance-Related Disorders / Q000175:diagnosis / Q000503:physiopathology / Q000523:psychology
D017447:Receptors, Dopamine D1; D017448:Receptors, Dopamine D2; D004298:Dopamine
Scand J Psychol. 2003 Jul;44(3):289-92
12914593
Proc Natl Acad Sci U S A. 1997 Mar 18;94(6):2569-74
9122236
Schizophr Res. 1998 May 4;31(1):19-26
9633833
Arch Gen Psychiatry. 1987 Jul;44(7):671-2
2955770
Am J Psychiatry. 2003 Jan;160(1):13-23
12505794
J Neurosci. 1997 Nov 1;17(21):8491-7
9334421
Am J Psychiatry. 2006 Nov;163(11):1969-77
17074949
Eur Psychiatry. 2002 Mar;17(1):9-16
11918987
J Neurosci. 2007 Jul 25;27(30):8080-7
17652599
Schizophr Bull. 2007 Sep;33(5):1071-81
17630406
J Neurosci. 2008 Jun 4;28(23):5976-82
18524902
Physiol Behav. 2002 Dec;77(4-5):513-7
12526992
Biol Psychiatry. 2000 Oct 1;48(7):627-40
11032974
J Cogn Neurosci. 2005 Oct;17(10):1497-508
16269092
Synapse. 1998 May;29(1):80-3
9552177
J Neurosci. 2001 May 15;21(10):3628-38
11331392
Neuropsychopharmacology. 2010 Jan;35(1):4-26
19812543
Med Hypotheses. 1976 Sep-Oct;2(5):203-11
9558
Int Rev Neurobiol. 2007;78:1-39
17349856
Mol Psychiatry. 2008 Mar;13(3):239, 267-76
17684497
Drug Alcohol Depend. 1995 May;38(2):95-137
7671769
Science. 1986 Dec 19;234(4783):1558-63
2878495
Proc Natl Acad Sci U S A. 2001 Jan 2;98(1):301-6
11134516
Nat Neurosci. 2008 Dec;11(12):1381-2
18978778
Curr Opin Neurobiol. 2004 Dec;14(6):769-76
15582382
Ann N Y Acad Sci. 2007 May;1104:35-53
17416921
J Neurosci. 2006 Aug 9;26(32):8368-76
16899732
Neuroimage. 2001 Nov;14(5):1159-67
11697947
Psychopharmacology (Berl). 2009 Sep;206(1):121-32
19521678
Eur Neuropsychopharmacol. 2008 Aug;18(8):589-99
18554874
J Neurosci. 2002 May 1;22(9):3708-19
11978847
J Neurochem. 1989 May;52(5):1655-8
2709017
Biol Psychiatry. 2009 Jun 15;65(12):1032-9
19195646
J Cogn Neurosci. 2009 Jul;21(7):1332-45
18752410
Neuron. 2004 Jul 22;43(2):261-9
15260961
Nat Neurosci. 2002 Mar;5(3):267-71
11865311
J Comp Neurol. 2002 Sep 2;450(4):345-65
12209848
Am J Psychiatry. 2003 Dec;160(12):2209-15
14638592
Nat Neurosci. 2002 Feb;5(2):169-74
11802171
Nature. 2007 Feb 8;445(7128):643-7
17287809
Psychopharmacology (Berl). 2008 Mar;196(4):673-84
18097655
Eur J Neurosci. 2006 Jul;24(1):305-13
16882026
J Neurosci. 2000 Mar 15;20(6):2369-82
10704511
Neuropsychopharmacology. 2008 Feb;33(3):473-9
17473838
Neuroscience. 2002;110(2):257-75
11958868
Lancet. 1995 Oct 28;346(8983):1130-1
7475604
J Neurosci. 2001 Aug 15;21(16):RC159
11459880
J Neurosci. 1993 Mar;13(3):900-13
8441015
Neural Netw. 2002 Jun-Jul;15(4-6):561-72
12371512
Neuropsychopharmacology. 1988 Sep;1(3):179-86
3075131
Pharmacopsychiatry. 2003 Nov;36 Suppl 3:S152-7
14677072
Curr Opin Neurobiol. 1996 Apr;6(2):228-36
8725965
J Comp Neurol. 1995 Mar 27;354(1):127-49
7542290
Neurosci Biobehav Rev. 1989 Summer-Fall;13(2-3):155-62
2682402
Synapse. 1999 May;32(2):71-9
10231127
Proc Natl Acad Sci U S A. 2000 Jul 5;97(14):8104-9
10884434
Eur J Nucl Med Mol Imaging. 2008 Jun;35(6):1147-58
18202844
Nervenarzt. 1999 May;70(5):399-407
10407835
Neuropsychopharmacology. 2003 Apr;28(4):787-94
12655326
Neuroimage. 2006 Jan 15;29(2):409-16
16139525
Psychopharmacology (Berl). 2006 Aug;187(2):222-8
16721614
Hum Brain Mapp. 2005 May;25(1):60-9
15846819
Psychopharmacology (Berl). 2006 Sep;187(4):486-97
16823591
Science. 2008 Aug 8;321(5890):848-51
18687967
Neuroreport. 2001 Dec 4;12(17):3683-7
11726774
Brain Res Brain Res Rev. 1993 Sep-Dec;18(3):247-91
8401595
Science. 1997 Mar 14;275(5306):1593-9
9054347
J Individ Psychol. 1974 May;30(1):98-113
4857199
Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9235-40
8799184
Schizophr Bull. 2009 Jul;35(4):668-74
19487337
Brain. 2007 Sep;130(Pt 9):2387-400
17690132
Psychopharmacology (Berl). 2007 Apr;191(3):813-22
17279377